Sarcomatrix Therapeutics Corp.

Sarcomatrix is a pre-clinical biotech developing first-in-class drugs to treat muscle wasting diseases, starting with the most severe forms, muscular dystrophies. Our potent α7β1 integrin enhancers promote muscle regeneration in all muscle types by stimulating satellite cells activation and increase myofiber fusion. Our path to age related (sarcopenia) and drug related (cachexia) muscle wasting is through muscular dystrophy.